Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study (Q51435694)

5 April 2018

title

Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study (English)

1 reference

5 April 2018

Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study (English)

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

23 December 2024

1 reference

4

Igle de Jong

1 reference

5 April 2018

Peter F.A. Mulders

1

object named as

Peter Mulders

1 reference

5 April 2018

author name string

Robert Hawkins

2

1 reference

5 April 2018

Paul Nathan

3

1 reference

5 April 2018

Susanne Osanto

5

1 reference

5 April 2018

Emilio Porfiri

6

1 reference

5 April 2018

Andrew Protheroe

7

1 reference

5 April 2018

Bijoyesh Mookerjee

9

1 reference

5 April 2018

Laura Pike

10

1 reference

5 April 2018

Peter Mulders

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22285180

23 December 2024

Igle de Jong

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22285180

23 December 2024

Carla M. L. van Herpen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22285180

23 December 2024

Juliane M. Jürgensmeier

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22285180

23 December 2024

Martin E. Gore

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22285180

23 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22285180

23 December 2024

publication date

28 January 2012

1 reference

5 April 2018

full work available at URL

http://www.ejcancer.com/article/S0959804911010719/pdf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22285180

https://api.elsevier.com/content/article/PII:S0959804911010719?httpAccept=text/xml

23 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

https://api.elsevier.com/content/article/PII:S0959804911010719?httpAccept=text/plain

23 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

European Journal of Cancer

23 December 2024

published in

1 reference

5 April 2018

volume

48

1 reference

5 April 2018

issue

4

1 reference

5 April 2018

page(s)

527-537

1 reference

5 April 2018

cites work

Global cancer statistics

1

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

23 December 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Recent advances and future directions in the management of metastatic renal cell carcinoma

23 December 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

23 December 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis

23 December 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

23 December 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Sunitinib: from rational design to clinical efficacy

23 December 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

23 December 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

23 December 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.

23 December 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

23 December 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia

23 December 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors

23 December 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

23 December 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

23 December 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer

23 December 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

23 December 2024

Q28304346

17

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

23 December 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

23 December 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

23 December 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Sorafenib in advanced clear-cell renal-cell carcinoma

23 December 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

23 December 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

23 December 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

23 December 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

23 December 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

23 December 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.EJCA.2011.12.022

23 December 2024

Identifiers

1 reference

5 April 2018

1 reference

5 April 2018